According to TipRanks, Abrahams is a 5-star analyst with an average return of 14.3% and a 56.11% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine.
Sionna Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $53.14.
Based on Sionna Therapeutics, Inc.’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $29.89 million. In comparison, last year the company had a GAAP net loss of $18.07 million
